european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
    • PL
  • Science News
  • Resources

Resources

Topic
All Analytics Antibody-drug conjugates Bioanalytics Biologics Biosimilars Biostatistics Cancer Cell culture Clinical trials Contamination Drug development Drug product Drug substance EMA FDA GMP Mabion Manufacturing Microbiology Partnership Proteins Regulatory Vaccines Veterinary biologics
Type
All Poster
release testing for-biologics

Release Testing for Biologics – Regulatory Requirements for GMP Compliance

Analytics, Manufacturing
antibody drug-conjugates development

Breaking Barriers in Antibody-Drug Conjugates Development

Antibody-drug conjugates, Cancer
Navigating regulatory approval of biologics: A guide for emerging biotechs Bringing a biologic to market is an increasingly complex task, especially for small and mid-sized biotech companies with limited regulatory infrastructure. Meeting sometimes divergent EMA and FDA expectations, following increasingly complex regulations, and avoiding pitfalls related to documentation requires early planning and cooperation. Cross-functional alignment is also crucial to avoid issues related to comparability and process development/design space/process validation. This whitepaper outlines the key considerations in regulatory planning and biologics development, offering actionable insights for sponsors preparing their therapies for market. Bringing a biologic to market is a complex task, but with strategic planning and the right partners, emerging biotechs can overcome the regulatory hurdles with confidence. Mabion’s deep understanding of both EU and US regulatory requirements, coupled with extensive hands-on experience in biologics development and manufacturing, positions us as an ideal partner for companies seeking to streamline their path to approval.

Navigating Regulatory Approval of Biologics: A Guide for Emerging Biotechs

EMA, FDA, GMP, Regulatory
protein characterization techniques

Protein Characterization Techniques for Biologics Development

Analytics, Biosimilars, Drug development, Proteins

Why Europe is Becoming a Global Hub for Biologics Manufacturing

Biologics, Manufacturing
biofilm risks in water systems

Risk Management Strategies for Biofilms in Water Systems used in Sterile Drug Manufacturing

Contamination, Regulatory
Previous 1 … 3 4 5 … 12 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap.

    Powered by

    Veneo